Literature DB >> 31797257

Decreasing Colectomy Rates in Ulcerative Colitis in the Past Decade: Improved Disease Control?

Hassan Ghoz1, Alex Kesler2, Sanne A Hoogenboom1, Filippo Gavi3, Bhaumik Brahmbhatt1, John Cangemi1, Paul T Kröner4.   

Abstract

BACKGROUND: Ulcerative colitis (UC) is primarily medically managed. Colectomy is required in patients with refractory disease or severe complications. Older studies have reported 20-year colectomy rates of over 50%, but recent studies showed decreased rates to 15%. Temporal trends in the use of colectomy in UC over the past decade (when the use of biologics has become widespread) are lacking.
METHODS: Case-control study using the National Inpatient Sample database for years of 2007, 2010, 2013, and 2016 was performed. The primary outcome was determining the temporal trends in the use of colectomy in hospitalized patients with UC. Secondary outcomes were determining the total number of admissions for patients with UC and associated trend in inflation-adjusted hospital costs, charge, and length of hospital stay (LOS). Multivariate regression analyses were used to adjust for other co-variables.
RESULTS: 443,043 patients with UC were identified, of which 19,208 underwent colectomy in the study period. The mean patient age was 52 years, and 47% were female. Five percent of hospitalized patients with UC underwent colectomy in 2007, while 2.7% of patients with UC had colectomy in 2016, representing a 46% decrease in colectomies in hospitalized patients in the study period. Patients with UC displayed adjusted odds of colectomy of 0.51 (p < 0.01), adjusted additional mean hospital costs decrease by - $2898 (p < 0.01), hospital charges increase by $26,554 (p < 0.01), LOS decrease by - 2.2 days (p < 0.01) in 2016 compared to 2007.
CONCLUSION: The odds of colectomy in UC patients decreased significantly over the past decade, likely secondary to improved medical care.

Entities:  

Keywords:  Healthcare costs; Hospital admissions; Inflammatory bowel disease; Inpatient epidemiology

Mesh:

Year:  2019        PMID: 31797257     DOI: 10.1007/s11605-019-04474-9

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  22 in total

1.  Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000.

Authors:  Conor G Loftus; Edward V Loftus; W Scott Harmsen; Alan R Zinsmeister; William J Tremaine; L Joseph Melton; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2007-03       Impact factor: 5.325

Review 2.  Inflammatory bowel disease: cause and immunobiology.

Authors:  Daniel C Baumgart; Simon R Carding
Journal:  Lancet       Date:  2007-05-12       Impact factor: 79.321

3.  Hospitalization trends of the Inflammatory Bowel Disease landscape: A nationwide overview of 16 years.

Authors:  Cláudia Camila Dias; Mafalda Santiago; Luís Correia; Francisco Portela; Paula Ministro; Paula Lago; Eunice Trindade; Alberto Freitas; Fernando Magro
Journal:  Dig Liver Dis       Date:  2019-02-06       Impact factor: 4.088

4.  Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.

Authors:  Johan Askling; C Michael Fored; Lena Brandt; Eva Baecklund; Lennart Bertilsson; Nils Feltelius; Lars Cöster; Pierre Geborek; Lennart T Jacobsson; Staffan Lindblad; Jörgen Lysholm; Solbritt Rantapää-Dahlqvist; Tore Saxne; Ronald F van Vollenhoven; Lars Klareskog
Journal:  Ann Rheum Dis       Date:  2007-01-29       Impact factor: 19.103

5.  Increasing rates and changing patterns of hospital admissions for patients with inflammatory bowel disease in Ireland: 1996-2001.

Authors:  C M Smyth; S Bacheer Picha; O Rathore; J Deasy; S E Patchett; F E Murray
Journal:  Ir J Med Sci       Date:  2005 Oct-Dec       Impact factor: 1.568

Review 6.  Medical therapy for ulcerative colitis.

Authors:  Niraj Jani; Miguel D Regueiro
Journal:  Gastroenterol Clin North Am       Date:  2002-03       Impact factor: 3.806

7.  Assessing comorbidity using claims data: an overview.

Authors:  Carrie N Klabunde; Joan L Warren; Julie M Legler
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

Review 8.  Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin: a systematic literature review.

Authors:  Kymberley Thorne; Laith Alrubaiy; Ashley Akbari; David G Samuel; Sian Morrison-Rees; Stephen E Roberts
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-04       Impact factor: 2.566

9.  High end of life health care costs and hospitalization burden in inflammatory bowel disease patients: A population-based study.

Authors:  Sanjay K Murthy; Paul D James; Lilia Antonova; Mathieu Chalifoux; Peter Tanuseputro
Journal:  PLoS One       Date:  2017-05-12       Impact factor: 3.240

10.  European evidence based consensus on surgery for ulcerative colitis.

Authors:  Tom Øresland; Willem A Bemelman; Gianluca M Sampietro; Antonino Spinelli; Alastair Windsor; Marc Ferrante; Philippe Marteau; Oded Zmora; Paulo Gustavo Kotze; Eloy Espin-Basany; Emmanuel Tiret; Giuseppe Sica; Yves Panis; Arne E Faerden; Livia Biancone; Imerio Angriman; Zuzana Serclova; Anthony de Buck van Overstraeten; Paolo Gionchetti; Laurents Stassen; Janindra Warusavitarne; Michel Adamina; Axel Dignass; Rami Eliakim; Fernando Magro; André D'Hoore
Journal:  J Crohns Colitis       Date:  2015-01       Impact factor: 10.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.